# HTH

> HTH is a VC fund in Milano backing Health Care and Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Milano, Italy
- Total investments: 7
- Last investment: Jun 2024
- Lead investor: 71%
- Last updated: Aug 2026
- Website: http://www.hthvc.com

HTH is a private Life Science Investment Company. Headquartered in Milan (IT), the company invests worldwide in Biotech, Medtech, Digital Health with a special focus on AI enabled technologies (but not limited to).

## Contacts

5 contacts available for HTH. Shizune tracks 1 team members at HTH. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/hth?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 86% |
| Biotechnology | 5 | 71% |
| Medical Device | 3 | 43% |
| Medical | 2 | 29% |
| Hardware | 1 | 14% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 29% |
| Series A | 2 | 29% |
| Pre-Seed | 1 | 14% |
| Series B | 1 | 14% |
| Series C | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 2 | 29% |
| Italy | 1 | 14% |
| France | 1 | 14% |
| Belgium | 1 | 14% |
| Switzerland | 1 | 14% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Michele Gaiotto | Managing Principal and Founder | 2 | https://shizune.co/investors/profile/michele-gaiotto |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EpilepsyGTx | EpilepsyGTx is a late-stage biotech company exploring cutting-edge gene therapies to improve the management of focal refractory epilepsy (FRE). | $10M | Seed | Jun 24, 2024 |  |
| Sensars | There are almost 5 millions of amputees, and even more nerve-injured persons, only in the USA and Europe. Together with commonly present neuropathic pain, and lost limb function (nerve injuries), they have no perception or control of the force required to hold or pick up objects and cannot feel their shape or consistency (when using prostheses). Acentury after the first prosthesis, electrodes, electronics and surgical expertise can be merged into the life-changing solution.Our venture is a synergistic effort converging expertise from microtechnologies, algorithms, electronics and clinical experimentation. We are an EPFL-based startup, founded by Francesco Petrini, Stanisa Raspopovic, and Silvestro Micera.Our mission is to re-enable upper, lower-limb amputees and nerve-damaged persons by:Restoring their complete sensory-motor functionality. Diminishing phantom limb pain. Enabling them to feel the artificial limb as part of their own body.From a market viewpoint, the nerve-injured persons do not have effective ways for function restoration, so we are proposing a novel tech and therefore generating a new market. As for amputees, the prosthetic limbs are getting more sophisticated but lack sensory feedback. We are constructing the game-changing functional improvement of the technology that will become the essential feature of the next-generation of prosthesis.Amputees and peripheral nerve damaged persons are in constant increase, mainly due to diabetes, car accidents, work injuries and wars. Among the most disabling consequences of these is the interruption of sensations flow from extremities to the brain. The absence of feedback and the perception of prosthesis as a foreign body are the primary reason for refusal to use prosthesis. Amputees cannot feel the shape or material of objects they are holding and have no perception of the force required to hold or pick up objects. Nerve-injured persons often have completely functionally unusable limbs. In 50-80% of cases, amputees and nerve-injured experience neuropathic pain from the missing part of the limb and drugs do not provide adequate relief. Providing them with an adequate sensory feedback would solve their problems. |  | Pre-Seed | Jun 11, 2024 |  |
| Lys Therapeutics | Lys Therapeutics is a biotechnology company developing drugs to treat patients suffering from neurovascular or neurodegenerative disorders. The company's main drug is a monoclonal antibody, Glunozumab, displaying an exclusive and groundbreaking mechanism of action, that triggers off-target toxicity through hyperactivation of both vascular andneuronal NMDA receptors (NMDAr). It causes the disruption of the blood-brain and blood-spinal cord barriers and strong neuronal excitotoxicity including stroke and multiple sclerosis. | $3.1M | Seed | Nov 14, 2022 |  |
| Leuko | Leuko Labs develops non-invasive white blood cell monitoring device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel,blood draws and laboratory infrastructure. Though its white blood cell monitoring device PointCheck, immunosuppressed patients can now be tested more frequently, moving towards improved quality of life and improved clinical outcomes. | $5M | Series A | Sep 23, 2022 |  |
| Neurofenix | Aiming to make rehabilitation more autonomous, enjoyable and accessible to stroke victims. | $6.9M | Series A | Aug 29, 2022 |  |
| Endostart | Endostart develops and manufactures a new generation of medical devices for gastrointestinal endoscopy. It creates Magnetic Balloon Technology, which improves endoscope performance and allows endoscopists to easily meet quality standards. It was founded in collaboration with CNR, public research institutions, and high-tech suppliers. | $10M | Series B | Jun 07, 2021 |  |
| Univercells | Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. | $84.9M | Series C | Feb 11, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [A11 Venture](https://shizune.co/investors/profile/a11-venture) — VC Fund, 1 deal together
- [AlbionVC](https://shizune.co/investors/profile/albion-vc) — VC Fund, 1 deal together
- [EUREKA! Venture SGR](https://shizune.co/investors/profile/eureka-venture) — VC Fund, 1 deal together
- [Good Growth Capital](https://shizune.co/investors/profile/good-growth-capital) — VC Fund, 1 deal together
- [IAG Capital Partners](https://shizune.co/investors/profile/iag-capital-partners) — VC Fund, 1 deal together
- [InHealth Ventures](https://shizune.co/investors/profile/inhealth-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does HTH invest in?

HTH invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact HTH?

Public channels for HTH include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at HTH?

The team at HTH includes Michele Gaiotto (Managing Principal and Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co